Reporting
CTNPT 045: Immune Response to COVID-19 Vaccination in People with HIV
Vaccines in a Time of Dual Pandemic: COVID-19 Vaccine in People with HIV
Learn MoreReporting
Vaccines in a Time of Dual Pandemic: COVID-19 Vaccine in People with HIV
Learn MoreCompleted
Clinical Evaluation of Itraconazole vs. Ketoconazole in HIV+ Patients with Oropharyngeal and/or Oesophageal Candidiasis
Learn MoreTerminated
A pilot randomized, open label study to evaluate the effect of a therapeutic HIV vaccine consisting of PENNVAX®-GP (gag, pol, env) and INO-9012 DNA vaccine delivered via electroporation on reducing HIV viral reservoirs in infected individuals, who initiated therapy during the acute/early phase of infection
Learn MoreCTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.